Showing results (71-80 of 94) with videos related to

Sort By:
Pageof 10
Human Pathology|April 2, 2021
Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencingC Eric Freitag, William R Sukov, Alan H Bryce, et al.
Molecular Cancer Therapeutics|June 12, 2015
Pilot Trial of Selecting Molecularly Guided Therapy for Patients with Non-V600 BRAF-Mutant Metastatic Melanoma: Experience of the SU2C/MRA Melanoma Dream TeamPatricia M LoRusso, Scott A Boerner, Mary Jo Pilat, et al.
European Urology|April 7, 2021
A Living, Interactive Systematic Review and Network Meta-analysis of First-line Treatment of Metastatic Renal Cell CarcinomaIrbaz Bin Riaz, Huan He, Alexander J Ryu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
JCO Oncology Practice|May 2, 2025
Prostate Cancer Foundation White Paper on Combination Therapy for Metastatic Hormone-Sensitive Prostate CancerSigrid V Carlsson, Pedro C Barata, Alan H Bryce, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Medrxiv : the Preprint Server for Health Sciences|May 5, 2025
Systemic treatment options for metastatic castration resistant prostate cancer: A living systematic reviewSyed Arsalan Ahmed Naqvi, Muhammad Umair Anjum, Arifa Bibi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 23, 2020
Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
The Journal of Clinical Investigation|June 8, 2021
FOXA1 overexpression suppresses interferon signaling and immune response in cancerYundong He, Liguo Wang, Ting Wei, et al.
Pageof 10